These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 30417939)
1. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study. Khelif A; Saleh MN; Salama A; Portella MDSO; Duh MS; Ivanova J; Grotzinger K; Roy AN; Bussel JB Am J Hematol; 2019 Feb; 94(2):200-208. PubMed ID: 30417939 [TBL] [Abstract][Full Text] [Related]
2. Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. Signorovitch J; Brainsky A; Grotzinger KM Qual Life Res; 2011 Dec; 20(10):1737-44. PubMed ID: 21533818 [TBL] [Abstract][Full Text] [Related]
3. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484 [TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice. Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925 [TBL] [Abstract][Full Text] [Related]
6. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632 [TBL] [Abstract][Full Text] [Related]
7. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. Garnock-Jones KP Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480 [TBL] [Abstract][Full Text] [Related]
9. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Yang R; Li J; Jin J; Huang M; Yu Z; Xu X; Zhang X; Hou M Br J Haematol; 2017 Jan; 176(1):101-110. PubMed ID: 27734464 [TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. Grainger JD; Blanchette VS; Grotzinger KM; Roy A; Bussel JB Br J Haematol; 2019 Apr; 185(1):102-106. PubMed ID: 30592022 [TBL] [Abstract][Full Text] [Related]
11. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States. Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608 [TBL] [Abstract][Full Text] [Related]
12. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. Zhang Y; Kolesar JM Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810 [TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia. Wu K; Thapar M; Farrell C; Hayes S; Guo H; Hou M; Zhang J Clin Ther; 2015 Jul; 37(7):1382-95. PubMed ID: 25929594 [TBL] [Abstract][Full Text] [Related]
14. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028 [TBL] [Abstract][Full Text] [Related]
15. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag. Tarantino MD; Fogarty PF; Shah P; Brainsky A Platelets; 2015; 26(1):93-6. PubMed ID: 24433306 [TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. Atkinson K Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797 [TBL] [Abstract][Full Text] [Related]
18. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Haselboeck J; Kaider A; Pabinger I; Panzer S Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750 [TBL] [Abstract][Full Text] [Related]
19. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054 [TBL] [Abstract][Full Text] [Related]
20. Eltrombopag for use in children with immune thrombocytopenia. Kim TO; Despotovic J; Lambert MP Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]